title: Biocompatibility of heparin-coated circuits in pediatric cardiopulmonary bypass.
abstract: In this study, we evaluated the biocompatibility of heparin-coated circuits in pediatric cardiopulmonary bypass (CPB). Eight patients were divided into 2 groups: the control group (Group C) and heparin-coated group (Group H). In Group H, CPB circuits, including the arterial pump, oxygenator, and cannulas were heparin-coated. Before, during, and after CPB, blood samples were obtained to assess the platelet counts (Plat), alpha 2-plasmin plasminogen inhibitor complex (PIC), thrombin-antithrombin III complex (TAT), C3 activation products (C3a), interleukin (IL)-6, IL-8, and polymorphonuclear neutrophil leukocyte (PMN) elastase. There was no significant difference in Plat, PIC, or TAT between groups. Group H showed significantly low levels of C3a (during and after CPB), PMN elastase (during CPB), and IL-6 (after CPB). These data demonstrated that in pediatric CPB, heparin-coated CPB circuits reduced the activation of complements and the production of PMN elastase and IL-6, suggesting the superior biocompatibility of the heparin-coated circuits.
authors.affiliation: First Department of Surgery, Osaka University Medical School, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Kagisaki
authors.forename: T
authors.initials: T
authors.lastname: Masai
authors.forename: K
authors.initials: K
authors.lastname: Kadoba
authors.forename: Y
authors.initials: Y
authors.lastname: Sawa
authors.forename: F
authors.initials: F
authors.lastname: Nomura
authors.forename: N
authors.initials: N
authors.lastname: Fukushima
authors.forename: H
authors.initials: H
authors.lastname: Ichikawa
authors.forename: T
authors.initials: T
authors.lastname: Ohata
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: S
authors.initials: S
authors.lastname: Taketani
authors.forename: H
authors.initials: H
authors.lastname: Matsuda
mesh_terms: D000925:Anticoagulants / Q000737:chemistry*; D000933:Antifibrinolytic Agents / Q000378:metabolism; D000990:Antithrombin III / Q000378:metabolism; D001672:Biocompatible Materials / Q000737:chemistry*; D002315:Cardiopulmonary Bypass / Q000592:standards*; D002675:Child, Preschool; D003176:Complement C3 / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005341:Fibrinolysin / Q000378:metabolism; D006493:Heparin / Q000737:chemistry*; D006801:Humans; D007223:Infant; D015850:Interleukin-6 / Q000378:metabolism; D016209:Interleukin-8 / Q000378:metabolism; D019272:Leukocyte Elastase / Q000097:blood; D008297:Male; D010107:Oxygenators, Membrane / Q000592:standards; D010447:Peptide Hydrolases / Q000378:metabolism; D010976:Platelet Count; D000979:alpha-2-Antiplasmin
chemical_list: D000925:Anticoagulants; D000933:Antifibrinolytic Agents; D001672:Biocompatible Materials; D003176:Complement C3; D015850:Interleukin-6; D016209:Interleukin-8; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D006493:Heparin; D010447:Peptide Hydrolases; D019272:Leukocyte Elastase; D005341:Fibrinolysin